fig2

Figure 2. In vitro dose-dependent effects of DRB18 on PCa cell lines and non-cancerous cells. (A) Five PCa cell lines were treated with 5, 10, 20, 30, 40, and 50 μM DRB18 for 24 h. DRB18 reduced relative cell viability in a dose-dependent manner; (B) DRB18 inhibited glucose uptake in a dose-dependent manner. Ace-1 cells were seeded in triplicate and treated with increasing doses of DRB18 for 15 min. Uptake of 2-deoxy-D-[3H] glucose was quantified by scintillation. One-way ANOVA; (C) Cell viability of Ace-1 cells and the canine kidney epithelial cell line MDCK following treatment with 5, 10, 20, 30, 40, and 50 μM DRB18 for 24 h. Cells were seeded in triplicate. Data were displayed as mean ± SD. Unpaired t-tests. *P < 0.05; **P < 0.01; *** P < 0.001. PCa: Prostate cancer; MDCK: Madin-Darby canine kidney cells.